Dr Melissa Wickremasinghe : General (internal) medicine , Respiratory medicine

Home
Dr Melissa Wickremasinghe

Not Fee assured
Awaiting verification
Open Referral network

Overview

About me

Melissa Wickremasinghe trained in respiratory medicine at the Royal Brompton Hospital and St Mary's hospital. She was awarded her PhD in respiratory epithelial cell chemokine networks in 2001 which she completed at Imperial College. She took up her consultant post in 2007 and has set up a lung fibrosis and sarcoidosis service at St Mary's hospital imperial college NHS helathcare trust which is now recognised and designated as one of only a few specialist centres in the UK. She hold a multi-disciplinary meeting for lung fibrosis and sarcoid which is the gold standard of care for all cases and especially so for complex cases. her ongoing research interests are in granulomatous lung diseases including sarcoidosis and tuberculosis which is reflected in her publications and also to her contributions to a recent definitive textbook called Sarcoidosis. She is also an expert in interventional bronchscopy performing complex procedures weekly include Endobronchial ultrasound and mediastinal node sampling.

Areas of interest

Pulmonary fibrosis; sarcoidosis

Medical secretaries

To pay your remaining balance, please go to
01702 382362

About me

External resources

linkedin

Current NHS consultant posts held

Consultant respiratory physician Imperial College Healthcare NHS trust, honorary Senior Lecturer imperial College

Research interests

Sarcoidosis, Interstitial Lung Disease, Lung fibrosis, symptom control of chronic fibrotic lung diseases, bronchiectasis, interventional bronchoscopy

(Additional) Languages spoken

Publications

Rituximab in severe, treatment-refractory interstitial lung disease.
Gregory J Keir, et al Respirology. 11/2013;

Importance of onsite cytopathology at endobronchial ultrasound.
Clare Elizabeth Honor Craig, Melissa Wickremasinghe et al
American Journal of Respiratory and Critical Care Medicine

Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-Î± antagonist therapy.
Aran Singanayagam et al Thorax 08/2013;

Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers.
Chloe I Bloom, et al PLoS ONE 01/2013; 8(8):e70630

Primary nodal anthracosis identified by EBUS-TBNA as a cause of FDG PET/CT positive mediastinal lymphadenopathy
Richard J. Hewitt, et al Respiratory Medicine Case Reports. 01/2013; 10:48â€“52

Obstructive lung function in sarcoidosis may be missed, especially in older white patients.
M Thillai,et al European Respiratory Journal 03/2012; 39(3):775-7.

A comparison between two strategies for monitoring hepatic function during antituberculous therapy.
Aran Singanayagam, et al American Journal of Respiratory and Critical Care Medicine 12/2011; 185(6):653-9

Sarcoidosis and tuberculosis cytokine profiles: indistinguishable in bronchoalveolar lavage but different in blood.
Muhunthan Thillai, et al PLoS ONE 01/2012; 7(7):e38083. Â· 3.73

Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study.
Neal Navani,et al Thorax 08/2011; 66(10):889-93

Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis.
Rosalyn Casey,et al PLoS ONE 01/2010; 5(12):e15619

Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction.
S Bloch,et al European Respiratory Review 12/2009; 18(114):295-

Non-tuberculous mycobacteria in patients with bronchiectasis.
M Wickremasinghe,et al Thorax 01/2006; 60(12):1045-51

Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network.
M I Wickremasinghe, et al The Journal of Immunology 11/1999; 163(7):3936-47

Courses offered to GPs

I will be conducting a GP imperial college trust education day 2014 on lung fibrosis, sarcoidosis, and symptom control in chronic fibrotic lung diseases.

My outcomes

My qualifications & training

Qualifications

FRCP Royal college of Physicians 2014
MRCP (UK) Royal College Physician 1994
PhD London University 2001
BSc Pharmacology (First Class Honours) London University 1988
MBBS (Honours, distinction in Pathology) Imperial College 1990

GMC registration

Reference number 3499320

Professional bodies (positions held - last 3 yrs)

IPF and Sarcoid registry British thoracic Society 2011

Details of entry to specialist register

Respiratory medicine, General Internal Medicine , 2007

Affiliations / memberships

British thoracic Society

My private practice

Practice hours

Practice
Day
Hours
Appt Bookings

St Mary's Hospital - Lindo Wing, W2 1NY
Monday
17:00 - 20:00
020 3312 1344

St Mary's Hospital - Lindo Wing, W2 1NY
Friday
14:00 - 17:00
020 3312 1344

Post treatment communication

Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.

In the event of an urgent query following treatment, Bupa members should use the following contact details

Please contact me by St Mary's switchboard on 02033120000 and ask for dr Wickremasinghe, non urgent enquires can be emailed to melissa.wickremasinghe@imperial.nhs.uk

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

E6310
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal masses - (1-5)

St Mary's Hospital - Lindo Wing (1-5) OneWelbeck (1-5)
X3510
IV sedation administered by operator - (1-5)

St Mary's Hospital - Lindo Wing (1-5) OneWelbeck (1-5)
20355
Initial out-patient consultation - remote - (1-5)
20365
Follow-up out-patient consultation - remote - (1-5)

Report this page Print page

Finder

Note: